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INTRODUCTION 
The most important danger to the uterine cervix is cancer. 
Carcinoma of the cervix is second in frequency only to breast 
cancer among the neoplasms causing CaJlcer deaths in females in 
the United States& (29) 
Considerable progress has been made in ttnderstanding the 
spread of cancers of the uterine cervix since the Weithei.rn op-
eration was devised and the first radiu.vn treatments given at the 
begi~~ing of the century. The relationship of the zones of 
effectiveness of internal radiu'U therapy and external ra.diation 
to the routes of spread of carcinomas of the cervix is well 
kncnm. (10) 
These main routes of cancer spread are along the vaginal 
mucosa, into the myometriu'U of the lower uterine segment, and 
from there tQ the fundus& Then it spreads into the network of 
lymph~tics of the paracervical areas and on to the parametria 
and the pelvic wall lymphatics. 
Cervical cancer may assume varied forms in its spread, 
and the complications which may result from this requires an 
adaptation of therapy to meet conditions, once treatment is 
begun. (11) 
The purpose of this study on the use of radiation in the 
treatment of cervical cancer is to survey the results of medical 
., 
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literature on this topic arid to show the results of radiation 
treatment on cases of cervical cancer treated at the University 
of Nebraska College of Medicine. 
HISTORY 
The principles of the treatment of squa~ous cell carcinoma 
of the cervix with irradiation has changed little since 1922. 
The use of radiant energy in the treatment of cancer of the cervix 
followed only two years after Becquerel inadvertently produced 
his self-inflicted atomic energy burn by carr,ying a tube of radium 
in his vest pocket. Cancer of the cervix was the first of the 
internal cancers to be successfully treated by radium, probably 
due to its favorable anatomic pOSition centered within the pelvis. 
As tL~e passed an American physician, Margaret Cleaves, 
treated a patient with cancer of the cervix using radium, in 1903. 
La.~er ~ 1907, Dominici (Laboratoire Biologigue liu Radium) in 
Paris announced his principles of filtered radiation~ Radium 
therapy then was developed principally in Stockholm and PariS. 
By 1922 radiation therapy was a practical and useful agent in 
cancer therapy, follOwing the introduction of external X-Ray as 
a supplement to radium, in 1918. 
B.Y 1929 the Radiumhemmet in Stockholm had adopted,the com-
bined therap,r in the management of most cervical cancer. But in 
Germany during and following World War I, the Germans were unable 
to acquire radium for medical use and thus their efforts turned 
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toward roehtgen radiation. Seitz and Wintz, using improved 
apparatus of greater voltage and employing filtration in their 
studies of irradiation of the pelvis by crossfiring through 
multiple portals, published (1920) an early account encouraging 
results in tne treatment of advanced cervical cancer. 
In the 1930 l s the 400 KV, 500 KV and 800 KV units beca."Ile 
available. Higher doses were hence given to the pelvic walls. 
By USing these doses and more efficient techniques, survival 
rates were further improved. Since World War II two new roentgen 
ray generators, cobalt 60 units and 15 to 25 MEV betatrons, have 
been used extensively in the management of cancers of the uterine 
cervix. (10) 
BACKGROUND INFORMATION 
The ultimate aim of radiotherapy of cancer of the cervix is 
to eradicate the primary disease and its extension into the sur-
rounding tissues. At the same time any injurious effects on the 
viability and function of the other pelvic structures must be 
minimized. 
The effects of radiation are multiple.. One of these is the 
cellular changes occurring, as first seen in the dividing nucleus. 
The nucleus aSSUJl1es abnormal forms and there is an arrest of 
division of the nucleus. An indirect effect of radiation on the 
tumor is due to the response of the stroma and blood vessels. (11) 
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Anemic patients and patients with local and systemic infec-
tions do not tolerate irradiation as well as do normal individuals. 
Thus the tumor response in these persons is not as satisfactory. (33) 
The patient receiving radiotherapy should be on a high 
protein, high calorie diet, increasing radiation tolerance. 
STAGES AND SUBSTAGES 
Cervical carcinoma is di videa and subdi videa. wi thin four 
stages. Stage I represents local disease confined to the cervix. 
Stage II cases are subdivided into Stage II-A and II-B in order 
to determine which cases are suitable for primary intracavitary 
radi~~ therapy. In Stage II-A the disease is limited to the 
upper two thirds of the vagina and there may be minimal invol-
vement of the parametria. In Stage II-B there is involvement of 
the lateral parametria and cancer extension almost to the pelvic 
wall, but there is still tumor free space between the tumor and 
the pelvic wall. 
A SUTVe.r of the literature (7) shows that the incidence of 
involvement of the pelvic wall lymph nodes is less than 25 per cent 
in Stage I and Stage II~A, around 40 to 50 per cent in Stage II-B, 
and above 60 per cent in Stage III cases. 
The emphasiS should be on the local disease which can be 
encompassed within the intracavitary radium therapy zone of 
adequate dosage in Stage I and Stage II-A. From Stage II-B 
on the disease is beyond the reach of intracavitary radium therapy. (11) 
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Stage III cases are also subdivided. Stage III-A represents 
a condition where only one pelvic wall is involved and Stage III-B 
includes those cases with both pelvic walls, or one pelvic wall 
and the la-wer one third of the vagina, involved. These Stage III.B 
cases have frozen or near-frozen pelves. Their prognosis is 
significantly worse than those patients of Stage III-A. 
The Stage IV cases are subdivided into those in which the 
disea.se is limited to the pel vis, and those in which there is 
distant metastases. Radical radiation thertp y is still indicate« 
in Stage IV cases without distant metastases. 
The following tables were compiled to show the treatment 
policies in two different conditions. Table I shows policies 
for carcinoma of the uterine cervix used in one institution; 
Table II su~arizes treatment policies for Primary Carcinoma of 
the Cervical Stump. 
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TABLE I 
Policy of Treatment in Carcinomas of the Uterine Cervix 
Stage 
I 
II-A 
n-B 
Treatment 
13,000-12,000 mgh in 2-4 insertions 
in 2-4 weeks, and 
3,000-4,000 rads to parametria 
and pelvic walls '** 
Same as Stage I 
4,000 rads to the whole pelvis in 
4 weeks with telecobalt followed 
by 4,500-6,555 mgh in 2 insertions 
il1 '2 iNeeks. 
5,000 rads to the whole pelvis in 
6 weeks with the telecobalt follow-
ed by 4,000-6500 mgh in one 
insertion. 
III-B 6,000 rads to the whole pelvis in 
7 weeks with telecobalt occasion-
ally with additional 2,000-3,000 
mgh of radiulllo 
IV Palliative. 
Except.ions 
If lesion is large, 2,000-
4,000 rads are given first 
to the whole pelvis in order 
to secure optimal geometric 
.conditions for intracavitary 
radium therapy. 
Same as Stage I 
For some selected cases 
of particularly infiltra-
ti ve stony hard squamous 
cell carcinomas in Stage 
II-A, less whole-pelvis 
radiation may be given 
in order to give more 
local radium therapy. 
A hysterectomy is perform-
ed in the large endocervi-
cal squamous cell carcinoma 
if regression is slow. 
Same as Stage II-B 
Same as Stage III-B when 
no distant metastases. 
i~In cases of associated pregnancy, or up to 1 year postpartum, 
4,000 rads are given to the whole pelvis because of increased 
probability of metastatic disease in the pelvic wall lymph nodes. 
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TABLE II 
Policy of Treatment of Primary Cancer of the Cervical Stump 
Stage 
I. 
II early 
II advanced 
III 
IV 
Treatment 
1. 72 hour radium applications 
2. 3500 r trans vag. X-Ray (140 KV Al H'lL) 
or if canal not located. Needle implant 
6000 r. 
1. 2000 r to entire pelvis in two weeks (10 RX) 
2. 4800 hr. radium application 
3. 3500 r trans vag. (140 KV 3mm Al HVL) 
4. 2000 r to parametrium 
1. 2000 r to entire pelvis in two weeks 
2. 48 hour radium application ** 
3. 2000 r to entire pelvis in two weeks 
4. 48 hour radium application 
~~y substitute 400 r T.V. for the two radium 
applications: 140 KV 3mm Al HVL 
hooo - 6000 r Entire pelvis (lateral ports 
in part) 
There have been many different techniques and applicators 
developed for intracavitar,r radium, but the technique and appli-
,cator per se are far less important than adherence to principles 
which have demonstrated their mel~t by favorable results over the 
years. (32) 
The dose to the parametria and pelvic wall depends upon the 
total milligram hours, the location of radium within the pelviS, 
and the respective loading of the tandem and colpostats. The 
main contributor to the pelvic wall lymph nodes from the intra-
cavitary radium system is the uterine radium because of the 
-7-
central location. The contribution of the vaginal radiation 
depends upon the location of the radium. This varies with age, 
size of tumor, and distortion ca.used by disease. 'Vlith high 
location within the pelvis the contribution to the obturator lymph 
nodes is approximately 1,000 r for each 4,400 mgh. The contribu-
tion to the hypogastric and external iliac lymph nodes is approxi-
mately half of that delivered to the obturator lymph nodes. (11) 
Doses to Point A and B are calculated for the patients fram 
tables. Point A refers to a point 2 cm lateral to the cervical 
canal and 2 cm from the mucosa of the lateral fornex and corres-
ponds to the paracervical tissue. Point B corresponds to the 
pelvic wall and the obturator lymph nodes. It is on the same 
level as Point A and 5 cm lateral to the uterine canal. The 
limiting tolerance is measured at Point A with the intention of 
delivering the maximum possible dose to Point B. External radi-
ation is calculated for the mid-pelvic tumor dose. 
CANCEROCIDAL A.'ifD TOLERANCE DOSES 
The ability to cure a cancer effectively by radiation without 
the destruction of the patient or her tissues is entirely depen-
dent upon the ability to deliver to the cancerous area a suffic-
ient dose of irradiation which kills the cancer and yet spares 
the normal tissue in the tumor area. So many variables modify 
the response in anyone situation that a wide biological range is 
used in expressing this cancerocidal dose. Also the time over 
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which the dose is given is important because of dose of 5000 r 
in 24 hours would cause tissue necrosis, but when given over a 
much longer period of 20 days, it would probably cause cancer 
regression without severe reactions. Another variable other than 
the time dose relationship is the sensitivity of the tumor to 
radiation. 
.. 
In the absence of obvious overt infection, the dose of choice 
is 8000 r delivered to Point A over a period of five weeks. (33,35) 
It is generally conceded that full irradiation by intracavitary 
sources to the entire pelvis is not practical because of the limit-
ations dictated by the tolerances of the central structures. Thus 
to obtain cancerocidal dosages to the lateral pelvis, supplemented 
therapy to the lateral areas is necessar,y. 
Iso curves are used in determining the dose rate being de-
livered to specific points. However, problems may occur due to 
anatomical deviations such as: the displacement farther or 
closer to the sources, of the bladder and rectum; or the unusual 
position or malposition of the applicator due to the tumor. 
The use of immediate localizaing fiL'1ls in the operating room 
serves as a good precaution. 
Thus an important contribution to the radio th~rapy is the 
introduction of direct measuring devices for monitoring the dose 
rate being delivered to specific points. The scintillation probe 
counter is an excellent practical tool for this purpose. (33) 
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The limiting ~actors of external radiation are the skin 
tolerance, minimized with rotational or multiple skin ports; 
and the rectum. The orthovoltage X-Ray machine, cobalt te1ether-
apy unit, Van de Graaff unit and the betatron, are available at 
the present time for supplemental radiotherapy. 
The cobalt teletherapy unit is used for most supplemental 
~herapy in this hospital at the Uni versi ty of Nebraska. The 
dosages reaching the midparametria1 areas are increased without 
increasing the sldn dosage itdt.h the cobalt unit, as compared 
with dosages of the orthovo1tage X-Ray machine. 
COMPLICATIONS OF RADIOT~~PY 
All radiation lihich is delivered to the pelvis for the treat-
ment of cervical cancer causes residual damage to some degree to 
all pelvic organs and structures. The extent of the damage varies 
from an insufficient allount to cause clinical symptoms, to an 
amount suffioient to cause permanent loss of functions. 
The small intestine is extremely sensitive to radiation and 
accounts for the major incidence of radiation sickness; however, 
the etiology of this illness cannot be accounted for entirely by 
this intestinal radiation. The skin, small intestines, large 
intestine, bladder, ureters, uterus, vagina, bone and ovaries may 
be involved and may lead to complications. 
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Generally the radiation injuries heal spontaneously if 
given enough time. Biopsies of pathologic areas subsequent to 
therapy should be delayed because radiated tissue is incapable 
of withstanding and combating infection. 
SUPER LETHA.LITY AND RADIO-RESISTANCE 
Super lethality is used to describe the condition in which 
the cancer lesion worsened after large doses of radiotherapy. 
The decrease in favorable results in Stage I lesions with an in-
crease in gamma radiation is explained by the fact that the major 
portion of the cancer lies within the limits of safe tolerance 
of therapeutic radiation dosage; and when additional radiation 
is given, complications secondary to excessive radiation arise 
and survival does not increase as might have been expec~ed. 
With later stages the major portion of tqe cancer is located 
in an area receiving less than a cancerocidal dose and an increase 
in dose will significantly increase the survival and will over-
shadow the secondary complications resulting from the radiation 
exceeding the safe-tolerance level. 
Re,dio-resistance in reference to cervical C8.,:ncer is really 
the relative resistance or insensitivity of tissue to the effects 
of radiation. Any tissue, normal or malignant, can be destroyed 
by radiation if the exposure is long enough. Thus the cancer is 
radio-resistant if it does not respond to the amount of radiation 
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that is safe to apply. 
"In our review of the cases it 101a5 found that th~ maj ori ty 
of failures of radiation as defined by local cervical persistance 
of cancer were due to errors in application rather than due to 
radioresistance." (32) 
There have been many attempts to try to predict radioresis-
tance prior to therapy. These include grading the cells, histo-
logic changes with small amounts of radiation, RNA/DNA ratio 
tissue cultures, and cytological techniques. Attempts to cOf'l.firm 
these tests have not been uniform. 
RESULTS OF IRRADIATION TREA~"T 
AT THE UNIVERSITY OF NEBRASKA SINCE 1258 
During the period fran January 1, 1958, to October.. , 1963, 
99 patients with squamous cell carcinoma of the cervix were re-
viewed. The ages, stages, type of treatment, and parity are 
important considerations. Table III which shows the distribu-
tion of ages of the University of Nebraska patients, follows: 
20-29 
Stage 0 11 
Stage I 2 
Stage II 
Stage III 
Stage IV 
I 
Total 13 
TABLE III 
Distribution by Age 
30-39 40-49 50-59 60-69 
15 8 4 
10 c ,.,; 2 3 
4 4 4 2 
3 3 3 
1 2 1 
29 21 11 13 
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70-79 80 and over 
3 
1 2 
~ 
.; 
1 
9 3 
Of this group one Stage 0 was treated with radiotherapy because 
she was a poor surgical risk. The remainder in this Stage were 
treated surgically. 
Summary of Sta~e I 
In Stage I, 25 patients were studied. The types of treat-
ment and survival rates are summarized below: 
TABLE IV 
Correlation of Treatment 'and Survival Rates in Stage I 
Procedure No.. of Patients Alive, tper cent of 2 yr. 
Cancer Free survivals 
After 2 Year~ 
Wertheim 10 10 100 
Hysterectomy 
Only 
TAIl Only 2 2* 100 
Vaginal 1 1 100 
Hysterectomy 
Onlv 
Radiation 3 1 33.3 
and 
SurgerY. 
Radiation 9 8 88.9 
Only 
Totals 25 22 88 (average} 
.. 'f()ne p atient has recorded recurrence after 25 months. 
The average dose of radiation in roentgens delivered to 
Point A in the 8 patients still living was 7,887 r. The dosage 
ranged from 4,470 r to 10,900 r. Four patients died following 
therapy; the average dose to Point A in this group was 6,575 r. 
However, 2 patients received 11,734 and 9,376 r. The patient 
receiving the ~734 r had received radiation to the abdomen 
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for another condition. She also had had a TAR performed. Due 
to this prior radiotherapy, she perhaps was not as sensitive to 
the radiation; for the dose she received is considered quite 
adequate. The patient receiving the 9,376 r dose also had an 
anterior exenteration performed five months following the radiat-
ion therapy. 
Two patients received doses too low to be cancerocidal. 
However, one of these patients received 2,579 r to Point A. 
w~en she died with a coronary 27 months later, no sign of disease 
was found. The other patient had a BUN of 40 and an anemia. 
The dose of 2,614 r to Point A seems very low and ineffective 
as treatment. 
In this Stage the complications-incidence was 33 1/3%. The 
complications of the radiation therapy were cystitis in one pa-
tient, bowel obstruction in one patient, and proctitis in two 
patients. The therapy on the patient with the bowel obstruction 
was stopped, but in the other patients, therapy was continued. 
A comparison of the complications of radiation therapy and 
the complications of surgery s·hows that there is a higher incidence 
with radiation. However, it must be kept in mind that surgery 
patients were carefully screened and had no noticeable cancer 
symptoms. They were patients on whom the Papanicolaou smears were 
done routinely and revealed abnormal smears with symptoms. 
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The radiation-treated patients, on the other hand, either 
came in with the complaint of vaginal bleeding, indicating later 
Stage I carcinoma, or they were poor surgical risks. It is true 
that the survival of the surgery patients was higher, but it must 
be noted that these patients were younger and in earlier Stage I 
conditions as compared to the radiation-treated patients. None 
of the pathological reports on these surgery patients whowed 
evidence of cancer spread to the nodes, thus indicating they 
were a more favorable group for survival. 
TABLE V 
Radiation Data for Stage I 
Stage I ••• living 
Case II Age Date Total pt. A 
Treated m17. hr. r 
1 62 10/61 5574 5768 
2 45 1/61 6600 10900 
4 39 3/61 6989 10564 
5 68 6/60 4658 4470 
8 52 8/61 4100 8495 
10 39 5/61 2190 8016 
11 30 2/61 6430 6191 
12 56 6/59 6083 8693 
Averages - ..... -- - 7104 7887 
Stage I . ••• died 
3 bb 510b 1540 2579 
6 42 10/60 7035 11734 
7 37 10/58 7916 9376 
9 77 6/rJ9 2614 2614 
Averages 4776 6575 
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Rectum Remarks 
r 
4172 Very obese; radium 
only, cystitis 
6216 Obese 
6100 Proctitis 
4385 Bowel Obst. 
6051 
7050 TAR and BSO prior 
to radiotherapy 
3279 Wertheim - 6 wks. 
after radium 
1488 
5630 
!-1oilths 
Alive Remarks 
--
27 Died of coronary 
No signoof disease 
Hysterectomy, 147. 
7896 26 TAR f'Tior Bad 
to Aba.omen for 
Another condition 
7465 11 Ant. Exenteration 
51. Proctitis 
--
2 Anem •• BUN 40 
7680 
Summary of Stage II 
A total of 17 patients were seen with Stage II disease. 
One patient refused therapy and was lost to followup in 1961. 
The dose of radiation is tabulated in Table VI. Thus, a total 
of 16 patients were treated with radiation. Nine (9) patients 
are living, 7 of whom were treated more than two years ago. One 
patient was treated less than 6 months ago and the other patient 
had a radical hysterectomy ohe year after radiation (dose to 
Point A was 7,000 r). The nodes were reported as negative 
(no evidence of carcinoma.) The last time this patient was seen, 
metastatic lesion to the spine was found and this was treated 
with radiation therapy. 
The average dose to the patients still living was 8,932 r 
to Point A.The average dose to Point A for patients who died 
was 7,161 r, or a dose, which, in most instances, is less than 
cancerocidal. One of the deaths of these patients was follow-
ing anterior exenteration. Another died with a eVA but had re-
sidual carcinoma. One of these patients had received 9,900,r to 
Point A but had a pelvic abscess. With this infection the radia-
tion was probably not as effective. Another patient developed a 
perforated uterus following radiation and died with peritonitis, 
secondary to this complication. The 2 year survival rate for 
this group is 5:3%. This is considerably lower than survival 
statistics from I,Yayo Clinic. (8) Their rate for five years 
was 72.8%. 
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Stage II ••• living 
Case Age Date 
110. Treated 
1 ~~ 6(63 3 12/59 
5 39 3 /60 
7 47 9/61 
10 48 5/60 
11 51 2/62 
12 51 5/59 
13 42 2/61 
14 64 1/61 
Averages - - -
Stage II ••• died 
2 35 5/60 
4 66 12/60 
6 88 7/59 
8 75 5158 
9 90 2/58 
15 32 9/60 
17 58 6/58 
Averages - - -
TABLE VI 
Radiation Data for Stage II 
Total Pt. A Rectum 
:mJit. hr. r r 
7746 9800 2350 
10416 10470 10149 
7707 10460 6650 
5760 9077 6260 
7614 8214 7320 
7078 7081 3542 
3634 5917 7210 
7471 10814 7874 
6984 8560 7504 
7157 8932 6540 
5639 6173 6962 
7734 9300 6780 
6480 5384 6200 
7300 6500 6180 
3500 5570 5400 
7564 9900 5800 
5220 5300 5008 
6234 7161 6050 
Summary of Stage III 
Months Remarks 
Alive 
Single Pul. Met. 
treated with irrad. 
nodes neg.; 
exenteration 
Anemia; 
ESO 9/60;Bil. 
uretero sigmoidos-
tomy. Hydroureter 
Mild proctitis 
Rad. Hys. 1 year 
after rad. Nodes 
and uterus neg. 
11/63 spine met. 
Oolitis 
Compression bladder 
BUN 21.5 
7 DieG! post. OPe 
Exenteration 
7 Died with OVA 
Diabetes 
11 Uterine perf.& 
Peritonitis 
35 BUN 23 
17 
10 Pelvic abscess 
22 Oordotomy 
A total of 14 patients were seen with Stage III disease. 
Only one patient is living following treatment, and she is free 
of disease as of 3 years and 8 months post-treatment. The average 
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dose to Point A in this Stage III group of patients was 6563 r with 
the range of 2944 r to 12,426 r. The incidence of complications 
is much higher in this group. Complications included: one intes-
tina1 obstruction, five ureteral obstruction, one proctitis, and 
two patients with severe anemia. One of these patients had a 
draining fistula (complication from original surgical treatment 
for carcinoma) two years prior to radiation. 
TABLE VII 
Radiation Data for Stage III 
Stage III ••• livin~ 
Gase Age Date Total pt. A Rectum Months 
No. Treated MR. hr. r r Alive 
1 75 4/60 6266 7080 6062 
Stage III ••• died 
2 47 2/b1 7033 12426 12208 30 
3 72 5/58 ---- 4290 4110 9 
4 51 9/58 4681 4734 6251 37 
5 65 11/60 3059 4464 3820 32 
6 65 1/59 6932 6455 7764 2 
7 7? 12/58 4016 4367 3809 2 
8 49 6/60 6940 9142 6443 40 
9 73 10/61 ---- 8600 8600 2 
10 73 3/60 5430 3675 3258 8 
11 45 4/59 5355 9124 6512 11 
12 67 2/60 1440 2944 2000 3 
13 56 5/60 6322 6463 4198 12 
14 58 8/59 6545 8633 7881 6 
Averages- - 5250 6563 5912 
-18-
liemarks 
Partial bowel obst. 
Hydronephritis 
Anemia 
Parametritis; 
Ureter obstruction 
Obst. ureter 
Diag. 2 yrs. prior; 
Hys. 2 yrs. prior; Abscesf 
Hydronephrosis 
BUN 25-30 
Met. to Skin 
3000 r radiation prior 
for draining fistula 
Proctitis, anemia 
Hematemisis,'dlverti-
culitis--stopped treat. 
Uretero ohst. anemia 
BUN 25 
Refused further ext. 
radiation; anemia 
Bronchiogenic Ca 
Summary of Stage rl 
A total of five patients were seen with Stage IV disease. 
Two patients were treated with radiation in this group. One was 
treated with an anterior exenteration yielding apparent success. 
One patient refused therapy and the other patient died before the-
rapy could be started. The radiation therapy in these patients 
was palliative because there was metastases in the lung in one 
patient and the other patient had received prior ramation. The 
patient with lung metastases received a 7000 r mid-pelvic dose. 
The survival rates for Stage III and IV are very poor and 
0% for Stage IV radiation therapy; however, the number of patients 
is too small to be Significant. 
RESULTS OF DIAGNOSTIC STUDIES 
Metastatic surveys were done on all Stage II and Stage IV 
patients. All Stage II cases were negative and four out of the 
five Stage IV's were negative in the X-Ray studies done on this 
group_ The intravenous pyelogram was the most consistent abnor-
mal finding with ather an obstructed ureter or a non-functioning 
kidney on one side. Seven IVP's were done on patients with Stage I 
disease and three "I-rere abnormal. According to one author, the 
abnormal findings on pretreatment pyelograms diminish the chance 
of the patient surviving .one year by approxL~te1y 50%. (31) 
In this study conducted at the University of Nebraska, there 
was a high number of patients in the 22-29 age group and two 
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of these patients had invasive carcinoma. One of these patients 
with invasive carcinoma had been followed closely with Papanicolaou 
sm.ears and after three dysplastic smears in a six month period, 
a cone was 00 ne showing invasive squa..'1l0US cell carcinorna. The 
high number of patients in the lower age groups is probably due 
to the type of patients seen.. Most of the patients were from. the 
lower economic groups and many have been pregnant several times 
in their teens. 
Two year survivals "tiere calculated for the various stages. 
S~~va1 statistics are reported as five year cures, tradition-
ally. However, for evaluating results of treatment, data based 
on survival without evidence of disease two years after treatment 
for cancer of the cervix are also considered reliable. (33) 
Eighty-five per cent of the patients with persistent cancer show 
evidence of persistence within two years. 
Between the second and fifth years subsequent to therapy, 
only 10% of the patients treated for cervical cancer demonstrate 
persistence of the cancer for the first time; and if the lL'1lita-
tions of the data are kept in mind, it is possible to evaluate 
adequately the results of treatment at various periods. 
It is of interest the percentages of blood types in this 
study. In this group of patients, 79 of the 99 had their blood 
typed and 46.7% were Q, 49.4% were!, 2.5% were ~, and 1.3% 
were ~. Of note is the low n~~ber of type ~, but because the 
-20-
study is small, this may be of little significance. 
A study was done by Garriga (14) on the relations of blood 
group to radiation response. Groups! and ~ responded in a very 
similar manner and when compared to group 2, the latter had, a 
signific~~tly better response to radiation therapy. 
CONCLUSIONS 
1. The primary treatment for invasive cervical carcinoma at 
the University of Nebraska Hospital has been intracavitary 
radium supplemented with external radiation. The exception 
would be a few highly favorable Stage lIS and especially those 
in the younger age groups where castration is n~ desirable. 
2. SurgerJ is apparently more effective in Stage I, but the pat-
ients were favorably selected whereas the patients with 
radiotherapy were not selected and had later Stage I disease. 
3. Salvage rates are low in the Stage II, III, and IV groups 
and also in the: patients in wh6mthe initial treatment 
was inadequate. 
4. Many failures of radiation are due to errors in application 
rather than due to radioresistance. 
5.. The status' of the urinary tract markedly i.."lfluences the survi-
val rates .. 
6. Earlier diagnosis through public education and more routine 
pelvic examinations combined with Papanicolaou smears at 
regular intervals promise the most L~ediate early diagnosis, 
thus benefiting the patient )n. th this disease. 
-21-
7. Carcinoma of the cervix is a curable disease when detected 
in its earliest stages. 
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